Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC

References

• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized Phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin–paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• ZhangLMaSSongXINFORM investigatorsGefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomized phase 3 trialLancet Oncol201213546647522512843
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor undenying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• TakanoTFukuiTOheYEGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in JapanJ Clin Oncol200826345589559518794545
   PubMed Web of Science ®Google Scholar
• TaniguchiKOkamiJKodamaKHigashiyamaMKatoKIntratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinibCancer Sci200899592993518325048
   PubMed Web of Science ®Google Scholar
• ChenZYZhongWZZhangXCEGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasOncologist201217797898522673630
   PubMed Web of Science ®Google Scholar
• ZhouQZhangXCChenZHRelative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerJ Clin Oncol201129243316332121788562
   PubMed Web of Science ®Google Scholar
• BaiHWangZChenKInfluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancerJ Clin Oncol201230253077308322826274
   PubMed Web of Science ®Google Scholar
• PunnooseEAAtwalSLiuWEvaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibClin Cancer Res20121882391240122492982
   PubMed Web of Science ®Google Scholar
• TaniguchiKUchidaJNishinoKQuantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomasClin Cancer Res201117247808781521976538
   PubMed Web of Science ®Google Scholar
• BaiHMaoLWangHSEpidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancerJ Clin Oncol200927162653265919414683
   PubMed Web of Science ®Google Scholar
• XuFWuJXueCComparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinibOnco Targets Ther2012543944723251095
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• YungTKChanKCMokTSTongJToKFLoYMSingle-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patientsClin Cancer Res20091562076208419276259
   PubMed Web of Science ®Google Scholar
• KimuraHKasaharaKShibataKEGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancerJ Thorac Oncol20061326026717409866
   PubMed Web of Science ®Google Scholar
• CoombesKRMorrisJSHuJEdmonsonSRBaggerlyKASerum proteomics profiling-a young technology begins to matureNat Biotechnol200523329129215765078
   PubMed Web of Science ®Google Scholar
• OkanoTKondoTFujiiKProteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinomaClin Cancer Res200713379980517289870
   PubMed Web of Science ®Google Scholar
• TaguchiFSolomonBGregorcVMass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyJ Natl Cancer Inst2007991183884617551144
   PubMedGoogle Scholar
• SalmonSChenHChenSClassification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimenJ Thorac Oncol20094668969619404214
   PubMed Web of Science ®Google Scholar
• VoortmanJPhamTVKnolJCGiacconeGJimenezCRPrediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profilingProteome Sci200973419728888
   PubMed Web of Science ®Google Scholar
• HeJShenDChungDUTumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapyInt J Oncol200935468369219724903
   PubMed Web of Science ®Google Scholar
• AmannJMLeeJWRoderHGenetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503J Thorac Oncol20105216917820035238
   PubMed Web of Science ®Google Scholar
• VillanuevaJPhilipJEntenbergDSerum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometryAnal Chem20047661560157015018552
   PubMed Web of Science ®Google Scholar
• QiuFLiuHYZhangXJTianYPOptimization of magnetic beads for MALDI-TOF MS analysisFront Biosci (Landmark Ed)2009143712372319273304
   PubMed Web of Science ®Google Scholar
• SchwambornKKriegRCGrosseJSerum Proteomic Profiling in Patients with Bladder CancerEur Urol200956698999619282097
   PubMed Web of Science ®Google Scholar
• VillanuevaJShafferDRPhilipJDifferential exoprotease activities confer tumor-specific serum peptidome patternsJ Clin Invest2006116127128416395409
   PubMed Web of Science ®Google Scholar
• ChangJTChenLCWeiSYIncrease diagnostic efficacy by combined use of fingerprint markers in mass spectrometry-plasma peptidomes from nasopharyngeal cancer patients for exampleClin Biochem200639121144115117014837
   PubMed Web of Science ®Google Scholar
• FreedGLCazaresLHFichandlerCEDifferential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samplesLaryngoscope20081181616818043497
   PubMed Web of Science ®Google Scholar
• RessomHWVargheseRSDrakeSKPeak selection from MALDI-TOF mass spectra using ant colony optimizationBioinformatics200723561962617237065
   PubMed Web of Science ®Google Scholar
• OrviskyEDrakeSKMartinBMEnrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinomaProteomics2006692895290216586431
   PubMed Web of Science ®Google Scholar
• CarboneDPSalmonJSBillheimerDVeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabLung Cancer201069333734020036440
   PubMed Web of Science ®Google Scholar
• KuiperJLLindJSGroenHJVeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenibBr J Cancer2012107111820182523079575
   PubMed Web of Science ®Google Scholar
• ChungCHSeeleyEHRoderHDetection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsCancer Epidemiol Biomarkers Prev201019235836520086114
   PubMed Web of Science ®Google Scholar
• LazzariCSpreaficoABachiAChanges in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsJ Thorac Oncol201271404821964534
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• KurataTMatsuoKTakadaMIs the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?J Thorac Oncol20061768469117409937
   PubMed Web of Science ®Google Scholar
• DouillardJYTargeting the target: a step forward for the treatment of non-small-cell lung cancerLancet Oncol201011210410520152760
   PubMed Web of Science ®Google Scholar
• FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
   PubMed Web of Science ®Google Scholar
• SaijoNTakeuchiMKunitohHReasons for response differences seen in the V15-32, INTEREST and IPASS trialsNat Rev Clin Oncol20096528729419390555
   PubMed Web of Science ®Google Scholar
• ZhuCQda Cunha SantosGDingKNational Cancer Institute of Canada Clinical Trials Group Study BR.21Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol200826264268427518626007
   PubMed Web of Science ®Google Scholar
• KobayashiTKoizumiTAgatsumaTA phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancerCancer Chemother Pharmacol201269512421246
   Web of Science ®Google Scholar
• YoshiokaHHottaKKiuraKOkayama Lung Cancer Study GroupA phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutationsJ Thorac Oncol2010519910419898258
   PubMed Web of Science ®Google Scholar
• NieQYangXNAnSJCYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphismEur J Cancer201147131962197021616658
   PubMed Web of Science ®Google Scholar
• IshikawaNDaigoYTakanoAIncreases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancersCancer Res200565209176918416230376
   PubMed Web of Science ®Google Scholar
• LinardouHDahabrehIJKanaloupitiDAssessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerLancet Oncol2008996297218804418
   PubMed Web of Science ®Google Scholar
• MaoCQiuLXLiaoRYKRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studiesLung Cancer20106927227820022659
   PubMed Web of Science ®Google Scholar
• AnSJChenZHSuJIdentification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking statusPLoS One20127e4010922768234
   PubMed Web of Science ®Google Scholar
• SunJMHwangDWAhnJSAhnMJParkKPrognostic and predictive value of KRAS mutations in advanced non-small cell lung cancerPLoS One201385e6481623724098
   PubMed Web of Science ®Google Scholar
• CarboneDPDingKRoderHPrognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialJ Thorac Oncol20127111653166023059783
   PubMed Web of Science ®Google Scholar
• MilanELazzariCAnandSSAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsJ Proteomics2012129110122771314
   PubMed Web of Science ®Google Scholar